Spotlight
Media
Publications:
Documents:
Videos:
Audio:
Biography
Peter Gulick is currently an associate professor of medicine at Michigan State University, College of Osteopathic Medicine, and serves as adjunct faculty in the College of Human Medicine and the College of Nursing.
He received training in two primary specialties: infectious diseases at the Cleveland Clinic Foundation and medical oncology at Roswell Park Memorial Institute.
Gulick is director of the MSU HIV/Hepatitis clinic where his primary area of interest is HIV therapy, as well as hepatitis B, hepatitis C and co-infection therapy.
In addition to teaching, Gulick has cared for HIV patients for 20 years and hepatitis C patients for 10 years.
He has served on the Lung Cancer Advisory Committee through the State of Michigan's Department of Community Health , as well as the HIV/AIDS Prevention and Intervention Section, the Michigan Cancer Consortium and the Region 1 Smallpox Planning Team.
Industry Expertise (3)
Writing and Editing
Research
Education/Learning
Areas of Expertise (3)
Hepatitis C
Hiv/Aids
Hepatitis B
Education (7)
Cleveland Clinic Foundation: Infectious Diseases 1983
Roswell Park Memorial Institute: Medical Oncology 1981
Cleveland Clinic Foundation: Internal Medicine 1980
Detroit Osteopathic Hospital: Internship 1977
Midwestern University: D.O. 1976
Michigan State University: M.D.
University of Michigan,: M.A., Health Managements and Policy
News (10)
Infectious disease expert praises vaccination rate
WKAR online
2021-03-11
With the number of people vaccinated against coronavirus growing daily, people in Michigan are starting to wonder about life after getting their shots. WKAR's Scott Pohl talks with Peter Gulick, an expert in infectious diseases at Michigan State University. Gulick is impressed with the pace of vaccinations. “There's a lot of resources, I think, to get people vaccinated. Now, it's not as restricted as it was before. As far as around the country, it depends on the state you're in and what requirements they have, and what issues they have, but I think that we still have a long way to go. I think we still have to really promote and push vaccines and try to get them implemented as effectively as possible.”
What does COVID-19 vaccine efficacy mean?
Verywell Health online
2021-02-16
Peter Gulick, associate professor of medicine at Michigan State University, tells Verywell that everyone should get the vaccine in order to decrease overall levels of the virus. “Just get vaccinated because the more people that get vaccinated, the closer we'll get to herd immunity,” Gulick says. Gulick explains that despite getting the vaccine, people may still transmit it to others. “Patients that get the vaccine may still be able to colonize," Gulick says. "They may have the virus up in their nose and it may not cause them disease where they feel symptoms." Because the disease might still be transmitted even after vaccination, Gulick recommends people continue wearing a mask, social distancing, and washing their hands regularly.
Who should get the Johnson & Johnson vaccine over the mRNA vaccines?
Live Science online
2021-02-15
While the Moderna and Pfizer two-shot regimens look, on paper, to be more efficacious, the Johnson & Johnson vaccine has an edge because it doesn't require a follow-up shot and it can be stored at ordinary refrigerator temperatures for months, said Peter Gulick, a professor of medicine and an infectious disease expert at Michigan State University College of Osteopathic Medicine. That could help with getting more people vaccinated especially those who may not come back for a second shot, as well as in locales where access is a problem, he said. The Johnson & Johnson shot's less stringent storage requirements could be an advantage in rural areas, Gulick said. "They can be put in a refrigerator and stored there, whereas Moderna, and definitely Pfizer, need much colder temperatures to keep their vaccine viable," Gulick told Live Science.
Arm pain after COVID-19 vaccine common
MedShadow online
2021-02-05
“The most common symptom patients are getting from these injections is pain. That's about 70% of the time,” says Peter Gulick, an associate professor of medicine at Michigan State University. He adds that his own arm was sore after he received the first shot of the Pfizer vaccine, but not after the second. Now, as more and more people are getting their shots, we're hearing details and personal stories, and a trend is emerging. Our vaccine side effect tracker has amassed more than 100 comments, many of which describe varying degrees of arm pain after the COVID-19 vaccine, along with redness, itching and swelling at the injection site.
MSU Infectious Disease Specialist Weighs In On Pfizer COVID-19 Vaccine Announcement
WKAR online
2020-11-11
The drug manufacturer Pfizer announced promising test results on a possible COVID-19 vaccine this week. It’s being reported that the vaccine could be submitted to the FDA for emergency use authorization as soon as the third week of November. WKAR’s Scott Pohl talks with MSU infectious disease specialist Dr. Peter Gulick about the Pfizer announcement.
Preflight Covid-19 testing is on the rise — the question is whether it works
CNBC online
2020-10-14
In calling for preflight testing last month, the IATA said that, “deployable solutions are expected in the coming weeks.” Medical experts say that may be premature. Polymerase chain reaction tests, also called PCR, can more accurately diagnose positive cases, said Dr. Peter Gulick, an infectious disease expert at Michigan State University. But those tests, which rely on a nasal swap, throat swab or saliva, “are run in a lab so it may take days to come back, and a patient may get infected during that time,” he said. That is the rub with PCR tests. Test too early, and a person’s chances of being infected after the test increase. Test too late, and the results may not be ready by departure time.
We Asked Doctors to Weigh In on the Biggest Coronavirus Myths Circulating Right Now
Yahoo! Finance online
2020-10-03
FACT: Even if you don't have symptoms, you can still be contagious. “It's possible that 70% to 80% of people may have mild to no symptoms, but I would still be very cautious because you may still be infectious,” says Peter Gulick, infectious disease expert at Michigan State University. What common symptoms should you expect? That landscape changes by the day, but as of now a high fever, dry cough, shortness of breath, and loss of sense of smell or taste are biggies to look out for. Some people are also thought to exhibit gastrointestinal signs like diarrhea, body aches, and upper respiratory symptoms like congestion. Keep yourself healthy by washing your hands regularly and staying inside.
Should You Invest in a UV Light to Sanitize Surfaces Like Your Phone? We Asked Experts
Pop Sugar online
2020-09-29
Does UV Light Actually Kill the Coronavirus? Peter Gulick, associate professor of medicine at Michigan State University, said that, while ultraviolet Cis the most effective form of UV light for combatting pathogens, "it's also potentially toxic to skin and mucous membranes."
Michigan has over 100,000 confirmed cases of coronavirus
Detroit Free Press online
2020-08-28
Michigan surpassed 100,000 confirmed coronavirus cases Friday. According to Peter Gulick, an infectious disease specialist and associate professor of medicine at Michigan State University, the state may need to prepare for 100,000 additional new cases by mid-January. "Nothing has changed as far as the virus goes," Gulick said to the Detroit Free Press earlier this month. "We have nothing beyond what we had in March (to treat it or prevent it). So, we still have to go by the old principles: Wear face masks, social distancing, don't go into crowds."
Michigan marks 100K coronavirus cases in 5 months. Experts warn we'll see at least 100K more
Detroit Free Press online
2020-08-17
By most measures, Michigan has managed to contain the spread better than many other states in a country that leads the world with 5.3 million cases and more than 168,000 deaths, according to the Johns Hopkins COVID-19 Global Case Tracker. But it's nowhere near over yet. The state should prepare to see another 100,000 new cases in the next five months, said Peter Gulick, an infectious disease specialist and associate professor of medicine at Michigan State University. "We'll be at more than 100,000" additional new coronavirus cases by mid-January, he predicted. "Nothing has changed as far as the virus goes," Gulick said. "We have nothing beyond what we had in March (to treat it or prevent it). So, we still have to go by the old principles: Wear face masks, social distancing, don't go into crowds."
Research Focus (1)
Translational HIV Research
I have a MSU Registry of over 500 HIV patients with protected data for HIV research. There are currently 2 HIH grants for HIV research. We also do Pharmaceutical sponsored Drug trials on New HIV medication.